Maarten Boers, EULAR 2021: Findings from the ULTIMATE Clinical Trial
It was great to talk with Prof. Maarten Boers (VU University Medical Center, Amsterdam, The Netherlands) to discuss the responsiveness and high discriminative validity of GLOESS and clinical outcomes of synovitis in PsA patients treated with secukinumab from the ULTIMATE Trial.
The abstract ‘Responsiveness of Ultrasound Synovitis and Clinical Outcomes in Psoriatic Arthritis Treated with Secukinumab: Data from the ULTIMATE Trial.‘ (POS0197), was presented at the European Congress of Rheumatology 2021, 2-5 June 2021.
Questions
- Could you tell us a little about Power Doppler ultrasonography and its advantages in the evaluation of synovitis in psoriatic arthritis (PsA)? (0:43)
- What were the objectives and design of the ULTIMATE clinical trial? (1:50)
- What were the findings of the study? (2:42)
- What conclusions were reached about the responsiveness and high discriminative validity of GLOESS in PsA? (3:39)
- How do you anticipate the role of ultrasound in PSA developing in the future? (5:04)
Disclosures: Maarten Boers has disclosures with BMS, Pfizer and Novartis.
Support:Â Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of EULAR 2021 (Virtual).
